KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.JAMA CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40960793PMC124446402025-Nov-010.98未发现恶性肿瘤人群证据。无 KM 图
Treatment-agnostic joint modeling of longitudinal circulating tumor dna predicts survival across first-line regimens in metastatic non-squamous NSCLC.Eur J Pharm Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40962073无 PMCID2025-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.JAMA OncolPMID 40996773PMC124648532025-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.JAMA OphthalmolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41066129PMC125120312025-Nov-010.98未发现恶性肿瘤人群证据。无 KM 图
Interactive Virtual Presence to Remotely Assist Parents With Car Seat Installation.PediatricsPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41077424无 PMCID2025-Nov-010.98未发现恶性肿瘤人群证据。无 KM 图
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial.Anesthesiology已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Fig. 1.:CONSORT/入组流程图;Fig. 2.:AI 判定为 other;Fig. 3.:森林图/亚组分析图。PMID 41085306PMC125130422025-Nov-010.98未发现恶性肿瘤人群证据。无 KM 图
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41125109无 PMCID2025-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41125112无 PMCID2025-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39174409无 PMCID2025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study.Clin Gastroenterol Hepatol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 39694205无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study.Clin Gastroenterol Hepatol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 39954913无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.J Addict Med已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。PMID 40193234PMC125776542025 Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial.Clin Transl Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40338282无 PMCID2025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration.Ophthalmol RetinaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40349982无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.J Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40381735无 PMCID2025-Nov0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.Int J HematolPMID 40418277PMC125720602025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Restoring TADS: RIAT reanalysis of the Treatment for Adolescents with Depression Study.Int J Risk Saf Med已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。PMID 40421808PMC125527602025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study.Eur J Heart Fail已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。PMID 40455066PMC127650482025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer.J Clin Pharmacol已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。PMID 40485075PMC125551012025-Nov0.95The study is a Phase III randomized trial in oncology with a drug intervention and original results, but it is a cardiac safety analysis focusing on QT prolongation, not a report of a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort focused on efficacy outcomes.无 KM 图
Hospitalizations as an outcome measure in COURAGE-ALS.Amyotroph Lateral Scler Frontotemporal DegenerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40503807无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial.Arthritis RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40509748无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.J Thorac OncolAI 判定该论文不进入自动 KM 提取:This is a pooled analysis of a phase II and a phase III trial; it is not a single Phase III RCT itself. The analysis combines results from multiple studies, including a non-randomized phase II component.PMID 40516821无 PMCID2025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40545237无 PMCID2025-Nov0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial.Amyotroph Lateral Scler Frontotemporal DegenerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40576049无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40617394无 PMCID2025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Primary cardioprotective effect of sacubitril/valsartan in breast cancer patients receiving adjuvant therapy.Eur J Heart Fail入排复审未纳入:The study is a randomized Phase III trial with a drug intervention and a clinical efficacy endpoint, but the endpoint (incidence of CTRCD) is not a time-to-event outcome as required for this cohort. It is a cardioprotective study, not an oncology efficacy trial.PMID 40637120无 PMCID2025-Nov0.85The study is a randomized Phase III trial with a drug intervention and a clinical efficacy endpoint, but the endpoint (incidence of CTRCD) is not a time-to-event outcome as required for this cohort. It is a cardioprotective study, not an oncology efficacy trial.无 KM 图
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.Clin Pharmacol Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图;Figure 5:非 KM 图。PMID 40637621PMC125981262025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40639387无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.J Clin PharmacolPMID 40641008PMC125550962025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related to Vasomotor Symptoms: Perspectives of Postmenopausal Women Receiving Elinzanetant in Phase III Clinical Trials.Patient已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。PMID 40650860PMC125591162025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.Ann OncolPMID 40680993PMC123992162025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.Ann OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40680994无 PMCID2025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40683357无 PMCID2025-Nov0.85This is an oncology, human, randomized Phase III trial with a drug-containing intervention (imiquimod) and original primary results. However, the primary efficacy endpoint is treatment failure at 24 months (a binary outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier analysis or hazard ratio for a time-to-event outcome is reported. Therefore, it does not meet the specific eligibility criteria for time-to-event efficacy endpoints.无 KM 图
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.J UrolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40711960无 PMCID2025-Nov0.95The trial is a Phase 3 randomized controlled trial in human oncology patients, but its primary and secondary outcomes are metabolic syndrome and related parameters (weight, waist circumference, HbA1c), not survival, progression, recurrence, death, or time-to-event efficacy outcomes required for eligibility.无 KM 图
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.J Clin OncolAI 判定该论文不进入自动 KM 提取:The trial is a randomized phase II/III trial, but it was terminated early due to futility after the interim analysis, with primary results based on the phase II component (426 patients included in interim analysis). The final phase III component was not completed, so it does not qualify as a completed Phase III randomized controlled trial.PMID 40720715PMC125736882025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies.CNS Drugs已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram。PMID 40730715PMC125151172025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy.Am J Cardiovasc Drugs已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 flow diagram;Fig. 3:AI 判定为 other。PMID 40750720PMC125947412025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.J UrolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40779615无 PMCID2025-Nov0.45The study is a randomized Phase 3 trial in oncology patients, but the intervention is a surgical mesh placement, not a drug. The primary endpoint is a binary radiographic outcome at 24 months, not a time-to-event endpoint like overall survival or progression-free survival.无 KM 图
Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40780241无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.J Allergy Clin Immunol PractPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40782846无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.CNS Drugs入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40802027PMC125152142025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
The pharmacokinetics and safety comparison of Zamerovimab and Mazorelvimab monoclonal antibodies vs. HRIG in category III rabies post-exposure prophylaxis: a stratified analysis by wound characteristics.BiologicalsPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40812204无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40816927无 PMCID2025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).Diabetes Obes MetabPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40842343无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.Clin Pharmacol Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40849898无 PMCID2025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.Paediatr Drugs已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。PMID 40874954PMC125342782025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.Am J Clin Dermatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 multi panel km。PMID 40886218PMC126155492025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.Cancer Commun (Lond)PMID 40899645PMC126298582025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.Am J Clin DermatolPMID 40900410PMC126155432025-Nov0.98未发现恶性肿瘤人群证据。已完成
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40908356无 PMCID2025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图